565 related articles for article (PubMed ID: 26018335)
21. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.
Caye A; Beldjord K; Mass-Malo K; Drunat S; Soulier J; Gandemer V; Baruchel A; Bertrand Y; Cavé H; Clappier E
Haematologica; 2013 Apr; 98(4):597-601. PubMed ID: 23065506
[TBL] [Abstract][Full Text] [Related]
22. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
Kuiper RP; Waanders E; van der Velden VH; van Reijmersdal SV; Venkatachalam R; Scheijen B; Sonneveld E; van Dongen JJ; Veerman AJ; van Leeuwen FN; van Kessel AG; Hoogerbrugge PM
Leukemia; 2010 Jul; 24(7):1258-64. PubMed ID: 20445578
[TBL] [Abstract][Full Text] [Related]
23. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
[TBL] [Abstract][Full Text] [Related]
24. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
25. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
Ofverholm I; Tran AN; Heyman M; Zachariadis V; Nordenskjöld M; Nordgren A; Barbany G
Leukemia; 2013 Sep; 27(9):1936-9. PubMed ID: 23538749
[No Abstract] [Full Text] [Related]
26. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
[TBL] [Abstract][Full Text] [Related]
27. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
[TBL] [Abstract][Full Text] [Related]
28. IKZF1 Deletions as a Prognostic Factor in Costa Rican Patients With Pediatric B-Cell Acute Lymphoblastic Leukemia.
Granados-Zamora M; Chaves-Herrera K; Morera-Araya E; Granados-Alfaro P; Valverde-Muñoz K; Soto-Herrera G; Santamaría-Quesada C
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e401-e406. PubMed ID: 32324698
[TBL] [Abstract][Full Text] [Related]
29. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
30. Combined analysis of
Cui L; Gao C; Wang CJ; Zhao XX; Li WJ; Li ZG; Zheng HY; Wang TY; Zhang RD
Leuk Lymphoma; 2021 Feb; 62(2):410-418. PubMed ID: 33054468
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
[TBL] [Abstract][Full Text] [Related]
33. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
[TBL] [Abstract][Full Text] [Related]
34. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
[TBL] [Abstract][Full Text] [Related]
35. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.
Schwab CJ; Chilton L; Morrison H; Jones L; Al-Shehhi H; Erhorn A; Russell LJ; Moorman AV; Harrison CJ
Haematologica; 2013 Jul; 98(7):1081-8. PubMed ID: 23508010
[TBL] [Abstract][Full Text] [Related]
36. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
38. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
[TBL] [Abstract][Full Text] [Related]
39. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.
Yang YL; Hung CC; Chen JS; Lin KH; Jou ST; Hsiao CC; Sheen JM; Cheng CN; Wu KH; Lin SR; Yu SL; Chen HY; Lu MY; Wang SC; Chang HH; Lin SW; Su YN; Lin DT
Cancer Sci; 2011 Oct; 102(10):1874-81. PubMed ID: 21740479
[TBL] [Abstract][Full Text] [Related]
40. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
